SHBC1192

E.VONG¹, G.H.LIM¹, X.XU¹, L.BHARWANI¹

Tan Tock Seng Hospital¹

Eribulin improves overall survival in patients with pre-treated metastatic breast cancer (MBC) based on available data in largely Western populations. We sought to analyse the efficacy and safety of eribulin in an Asian real-world setting.

A total of 50 MBC patients were treated with eribulin at the Johns Hopkins Singapore International Medical Centre and TTSH from July 2011 to March 2017. Data from 46 patients was retrospectively analysed; 4 patients were excluded due to incomplete medical data.

The median age of the patients was 60 (range 36-73). 93.5% had an ECOG performance status of 0-1. Most patients had lung (70%), bone (70%) and liver (59%) metastases. 67%, 35% and 15% of patients had HR-positive, HER2-positive and triple negative disease respectively. The median number of lines of therapy received in the metastatic setting was 2.5 (range 1-5). 63% and 93.5% of patients had received prior anthracycline and taxane.

The ORR based on RECIST v1.1 was 34.8% (95% CI 22-50) and the DCR was 50% (95% CI 36-64). The median PFS was 3.5 months (95% CI 2.8-5.0) and the median OS was 8.1 months (95% CI 5.3-11.0). The most common grade 3-4 toxicities based on CTCAE v4.0 were neutropaenia (41%), anaemia (11%) and febrile neutropaenia (6.5%). Dose reductions occurred in 37% of patients most commonly due to neutropenia. 3 patients discontinued eribulin due to toxicity.

Our study demonstrates the clinical efficacy and manageable tolerability of eribulin in an Asian real world setting and supports its use in Asian patients with pre-treated MBC.